Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bard Announces Exclusive Agreements for Distribution of Gastrointestinal Devices.


Business Editors, Health/Medical Writers

MURRAY HILL, N.J.--(BUSINESS WIRE)--March 27, 2000

C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (BCR BCR B Cell Receptor
BCR Business Communications Review (magazine)
BCR Banca Comerciala Romana (Romanian bank)
BCR Breakpoint Cluster Region
BCR Benefit/Cost Ratio
BCR Bay City Rollers
: NYSE NYSE

See: New York Stock Exchange
) today announced it has entered into exclusive agreements with Olympus Europe and KeyMed for the European, Middle-East, and African distribution of Bard's disposable gastrointestinal (GI) and endoscopic en·do·scope  
n.
An instrument for examining visually the interior of a bodily canal or a hollow organ such as the colon, bladder, or stomach.



en
 accessories for gastroenterological procedures. The Bard products will be available immediately through Olympus Europe and KeyMed - both wholly owned subsidiaries of Japan-based Olympus Optical Co., Ltd. - and will be manufactured by Bard's Interventional Products division, based in Billerica, MA.

"These agreements are complementary to both companies and accomplish several critical goals," said Bard Chairman and Chief Executive Officer, William H. Longfield. "By appointing Olympus Europe and KeyMed as exclusive distributors for our GI products, Bard has gained sole access to the best distribution channels in Europe, which will significantly enhance our market share and Bard's presence in the GI business outside of the U.S.," Longfield explained. "Additionally, these agreements provide Olympus Europe and KeyMed - as well as the respective physicians and health care providers - with access to Bard Interventional's state-of-the-art product lines," he said.

Bard's disposable GI and endoscopic product lines covered by this agreement include biopsy forceps biopsy forceps Surgery A disposable forceps used during minimally invasive GI and urologic endoscopy for collecting biopsies , biliary accessories, polypectomy snares used to remove polyps Polyps
A tumor with a small flap that attaches itself to the wall of various vascular organs such as the nose, uterus and rectum. Polyps bleed easily, and if they are suspected to be cancerous they should be surgically removed.
 in the colon, and a variety of other endoscopic products used to diagnose and treat gastrointestinal disorders. These products are a natural supplement to Olympus' line of reusable devices, and enable Olympus to offer the most extensive line of state-of-the-art flexible endoscopes and endoscopic accessories available.

Excluded from the Bard/Olympus agreement are Bard's endoscopic feeding devices currently marketed and sold by Bard in Europe, Middle-East, and Africa which will continue to be sold directly from Bard.

C. R. Bard, Inc. (www.crbard.com) is headquartered in Murray Hill, New Jersey
For other places with the same name, see Murray Hill.
Murray Hill is an unincorporated area within portions of both Berkeley Heights and New Providence, located in Union County in north-central New Jersey.
, and is a leading multinational developer, manufacturer, and marketer of health care products in the fields of urology, oncology, and vascular, and in surgical specialty products.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 27, 2000
Words:321
Previous Article:Wireless MD and Devon Health Services Team to Provide Wireless Connectivity to Physicians.
Next Article:GS Mort Sec., Ser 1998-GLII $28.2M Class G On RatingAlert.
Topics:



Related Articles
SLT files suit against C.R. Bard for breach of contract.
Hydromer, Inc.--HYDI--Today Announced It has Entered Into Agreements With CR Bard, Inc.--BCR--.
Bard Announces Endologix Agreement for AAA Device.
Bard Announces Lumitex Agreement for New Cold Light Technology; Bard Licensed to Market Unique Product in Urology and Gynecology Applications.
Bard Interventional Products Enters Into Exclusive Agreement With Olympus Japan Co., Ltd.
Theragenics Announces TheraSeed Distribution Agreement With C.R. Bard, Inc.
C. R. Bard Announces TheraSeed Distribution Agreement With Theragenics Corporation.
Trimedyne Announces Management Changes, Increased Revenues and Favorable Court Decision.
Spire Receives $5 Million Catheter License Payment; Second Payment for Catheter License Agreement with Bard Access Systems.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles